
Publication Venue For

Bayesian variable selection for understanding mixtures in environmental exposures..
40:48504871.
2021

Propensity score weighting for covariate adjustment in randomized clinical trials..
40:842858.
2021

Simultaneous record linkage and causal inference with propensity score subclassification..
37:35333546.
2018

Identifying optimal dosage regimes under safety constraints: An application to long term opioid treatment of chronic pain..
37:14071418.
2018

Sample size determination for jointly testing a causespecific hazard and the allcause hazard in the presence of competing risks..
37:13891401.
2018

Accommodating the ecological fallacy in disease mapping in the absence of individual exposures..
36:49304942.
2017

A comparison of risk prediction methods using repeated observations: an application to electronic health records for hemodialysis..
36:27502763.
2017

Bayesian multinomial probit modeling of daily windows of susceptibility for maternal PM2.5 exposure and congenital heart defects..
35:27862801.
2016

Bayesian reclassification statistics for assessing improvements in diagnostic accuracy..
35:25742592.
2016

Multiple imputation for harmonizing longitudinal noncommensurate measures in individual participant data metaanalysis..
34:33993414.
2015

Incorporation of individualpatient data in network metaanalysis for multiple continuous endpoints, with application to diabetes treatment..
34:27942819.
2015

Change point testing in logistic regression models with interaction term..
34:14831494.
2015

A marginalized zeroinflated Poisson regression model with overall exposure effects..
33:51515165.
2014

Imputation of confidential data sets with spatial locations using disease mapping models..
33:19281945.
2014

Correction to How to interpret a small increase in AUC with an additional risk prediction marker: Decision analysis comes through [Statist. Med. (2015) 33, 22, 39463959] DOI: 10.1002/sim.6195.
34:900.
2014

A latent factor linear mixed model for highdimensional longitudinal data analysis..
32:42294239.
2013

Propensity score weighting with multilevel data..
32:33733387.
2013

Phase II clinical trials with timetoevent endpoints: Optimal twostage designs with onesample logrank test
2013

A spatiotemporal absorbing state model for disease and syndromic surveillance..
31:21232136.
2012

Sensitivity analysis for unmeasured confounding in principal stratification settings with binary variables..
31:949962.
2012

Correction: Evaluation metrics for biostatistical and epidemiological collaborations.
31:600.
2012

Authors' reply.
31:9697.
2012

A minmax combination of biomarkers to improve diagnostic accuracy.
30:3266.
2011

The end of the beginning: A commentary on 'Evaluation metrics for biostatistical and epidemiological collaborations': A rejoinder.
30:27832784.
2011

Hierarchical spatial modeling of uncertainty in air pollution and birth weight study..
30:21872198.
2011

Estimating propensity scores with missing covariate data using general location mixture models..
30:627641.
2011

Comparative effectiveness research: Policy context, methods development and research infrastructure..
29:19631976.
2010

Joint Bayesian analysis of birthweight and censored gestational age using finite mixture models..
29:17101723.
2010

A bivariate survival model with compound Poisson frailty..
29:275283.
2010

A robust method for comparing two treatments in a confirmatory clinical trial via multivariate timetoevent methods that jointly incorporate information from longitudinal and timetoevent data..
29:7585.
2010

Response to ‘Net reclassification improvement and decision theory’ by Vickers et al
..
28:526528.
2009

'Smooth' inference for survival functions with arbitrarily censored data..
27:54215439.
2008

Empirical estimation of life expectancy from large clinical trials: use of lefttruncated, rightcensored survival analysis methodology..
27:55255555.
2008

Covariate adjustment for twosample treatment comparisons in randomized clinical trials: a principled yet flexible approach..
27:46584677.
2008

A distributionfree test of constant mean in linear mixed effects models..
27:38333846.
2008

Estimation of propensity scores using generalized additive models..
27:38053816.
2008

Sample size calculation for the weighted rank statistics with paired survival data..
27:33503365.
2008

Joint modeling of sensitivity and specificity..
27:17451761.
2008

Randomized phase II trials with a prospective control..
27:568583.
2008

Comments on 'Integrated discrimination and net reclassification improvements  Practical advice'.
27:207212.
2008

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond..
27:157172.
2008

Relative quantification based on logistic models for individual polymerase chain reactions..
26:55965611.
2007

Morphometric analysis for early detection of changes in cellular structure in a toxicological experiment..
26:52535266.
2007

A correlated frailty model with longterm survivors for estimating the heritability of breast cancer..
26:37223734.
2007

Analysis on binary responses with ordered covariates and missing data..
26:34433458.
2007

Bayesian methods for searching for optimal rules for timing intercourse to achieve pregnancy..
26:19201936.
2007

Stability analysis for drugs with multiple active ingredients..
26:15121517.
2007

Bivariate random effect model using skewnormal distribution with application to HIVRNA..
26:12551267.
2007

Choice of time scale and its effect on significance of predictors in longitudinal studies..
26:13431359.
2007

Performance assessment for radiologists interpreting screening mammography..
26:15321551.
2007

Inference for casecontrol studies when exposure status is both informatively missing and misclassified..
25:40654080.
2006

Bayesian semiparametric ROC analysis..
25:39053928.
2006

Estimating measures of diagnostic accuracy when some covariate information is missing..
25:29812993.
2006

Interval estimation for treatment effects using propensity score matching..
25:22302256.
2006

Author's reply [4].
25:14371438.
2006

On noninferiority margin and statistical tests in active control trials..
25:11011113.
2006

Rank tests for clustered survival data when dependent subunits are randomized..
25:361373.
2006

Examining accuracy of screening mammography using an event order model..
25:267283.
2006

Assay validation for leftcensored data..
24:33473360.
2005

A multiple testing procedure to associate gene expression levels with survival..
24:30773088.
2005

Sample size for a twogroup comparison of repeated binary measurements using GEE..
24:25832596.
2005

Statistical inference for cancer trials with treatment switching..
24:17831790.
2005

Assessing intra, inter and total agreement with replicated readings..
24:13711384.
2005

A practical approach for comparing means of two groups without equal variance assumption: H. Wang and S. Chow, Statistics in Medicine 2002; 21:31373151..
24:817818.
2005

Analysis of clinical data with breached blindness: by SheinChung Chow and Jun Shao Statistics in Medicine 2004; 23:11851193..
24:819821.
2005

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study..
23:29372960.
2004

Strength of accumulating evidence and data monitoring committee decision making..
23:26592672.
2004

Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation..
23:21092123.
2004

Sample size determination for comparing several survival curves with unequal allocations..
23:17931815.
2004

Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?.
23:15031505.
2004

Analysis of clinical data with breached blindness..
23:11851193.
2004

On the estimation of the binomial probability in multistage clinical trials..
23:881896.
2004

Admissible twostage designs for phase II cancer clinical trials..
23:561569.
2004

Growth velocity assessment in paediatric AIDS: smoothing, penalized quantile regression and the definition of growth failure..
23:509526.
2004

The heritability of causespecific mortality: a correlated gammafrailty model applied to mortality due to respiratory diseases in Danish twins born 18701930..
22:38733887.
2003

ROC methodology within a monitoring framework..
22:34733488.
2003

Comparing linear and nonlinear mixed model approaches to cosinor analysis.
22:31953211.
2003

A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present..
22:27112721.
2003

Evaluating medical diagnostic tests at the subunit level in the presence of verification bias..
22:21612176.
2003

Power calculations for large multiarm placebocontrolled studies of dichotomous outcomes..
22:19431954.
2003

Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV1 RNA in blood and semen..
22:14571464.
2003

Sample size estimation for GEE method for comparing slopes in repeated measurements data..
22:13051315.
2003

A parametric model for longterm followup data from phase III breast cancer clinical trials..
22:339352.
2003

Missing data in the 2 x 2 table: patterns and likelihoodbased analysis for crosssectional studies with supplemental sampling..
22:517534.
2003

In vitro bioequivalence testing..
22:5568.
2003

A practical approach for comparing means of two groups without equal variance assumption..
21:31373151.
2002

The ebb and flow of the NHS waiting list: how do recruitment and admission affect eventbased measures of the length of 'timetoadmission'?.
21:29913009.
2002

Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?.
21:28892897.
2002

Industry perspectives on ICH guidelines..
21:29492957.
2002

A multistate model for the genetic analysis of the ageing process..
21:25112526.
2002

Reproducibility probability in clinical trials..
21:17271742.
2002

Individual bioequivalence testing under 2x3 designs..
21:629648.
2002

The impact of the international guideline entitled Statistical Principles for Clinical Trials (ICH E9)..
20:25492560.
2001

Using observational data to estimate prognosis: an example using a coronary artery disease registry..
20:25052532.
2001

Improving the fit of bivariate smoothing splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies..
20:24892504.
2001

Evaluation of an adjusted chisquare statistic as applied to observational studies involving clustered binary data..
20:21492161.
2001

Sample size calculations for clustered binary data..
20:19711982.
2001

Twophase shelflife estimation..
20:12391248.
2001

Bayesian analyses of longitudinal binary data using Markov regression models of unknown order..
20:755770.
2001

Tests for 2 x K contingency tables with clustered ordered categorical data..
20:785794.
2001

Assessing human fertility using several markers of ovulation..
20:965978.
2001

Detecting treatmentbycentre interaction in multicentre clinical trials..
20:193213.
2001

Strategic use of statistical thinking in drug development..
19:32113217.
2000

Preface. Bioequilavence measures..
19:2719.
2000

The bootstrap procedure in individual bioequivalence..
19:27412754.
2000

First steps in analysing NHS waiting times: avoiding the 'stationary and closed population' fallacy..
19:20372051.
2000

Modelling covariance structure in the analysis of repeated measures data..
19:17931819.
2000

On statistical analysis for placebochallenging designs in clinical trials..
19:10291037.
2000

Comparison of diagnostic markers with repeated measurements: a nonparametric ROC curve approach..
19:511523.
2000

Prognostic models based on literature and individual patient data in logistic regression analysis..
19:141160.
2000

Accounting for unreported and missing intercourse in human fertility studies.
19:665679.
2000

The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials..
18:34353451.
1999

Evaluating the exposure and disease relationship with adjustment for different types of exposure misclassification: a regression approach..
18:27952808.
1999

Testing proportionality in the proportional odds model fitted with GEE..
18:14191433.
1999

A regression model for multivariate random length data..
18:199211.
1999

Combining classification trees using MLE.
18:727740.
1999

Comparing riskadjustment methods for provider profiling..
16:26452664.
1997

Testing homogeneity of intrarun variance parameters in immunoassay..
16:17651776.
1997

Bayesian inference in twophase prevalence studies..
16:11211133.
1997

Statistical methods for twosequence threeperiod crossover designs with incomplete data..
16:10311039.
1997

The impact of patient compliance on drug concentration profile in multiple doses..
15:659669.
1996

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors..
15:361387.
1996

Polynomials with asymptotes for longitudinal data..
15:6174.
1996

A statistic for comparing two correlated markers which are prognostic for time to an event..
14:22172225.
1995

The restricted cubic spline as baseline hazard in the proportional hazards model with step function timedependent covariables..
14:21192129.
1995

Multistate models and diabetic retinopathy.
14:19751983.
1995

Smoothing splines for longitudinal data.
14:12351248.
1995

Nonparametric estimation for the difference or ratio of median failure times for paired observations..
14:275281.
1995

Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in nonsmallcell lung cancer..
13:13131327.
1994

The case against independent monitoring committees..
13:14111414.
1994

Assays for recombinant proteins: a problem in nonlinear calibration..
13:11651179.
1994

Twostage sampling in pharmaceutical applications..
12:19992008.
1993

A survey of monitoring practices in cancer clinical trials..
12:435450.
1993

DATA MONITORING AND INTERIM ANALYSES IN THE PHARMACEUTICALINDUSTRY  ETHICAL AND LOGISTICAL CONSIDERATIONS  MONITORING OF CLINICALTRIALS AND INTERIM ANALYSES FROM A DRUG SPONSORS POINTOFVIEW  DISCUSSION.
12:493495.
1993

Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations..
12:471479.
1993

Discussion: Stephen George, a survey of monitoring practices in cancer clinical trials: Stephanie Green and John Crowley, data monitoring committees for Southwest Oncology Group clinical trials.
12:457459.
1993

Analysing the relationship between change in a risk factor and risk of disease..
11:783797.
1992

Test for batchtobatch variation in stability analysis..
11:269270.
1992

Correction: Outlier detection in bioavailability/bioequivalence studies (Statistics in Medicine (1990) 9 (549558)).
11:425.
1992

On the estimation of total variability in assay validation..
10:15431553.
1991

Analyses of black and white differentials in the age trajectory of mortality in two closed cohort studies..
10:10431059.
1991

Methods for the analysis and assessment of clinical databases: the clinician's perspective..
10:617628.
1991

Outlier detection in bioavailability/bioequivalence studies..
9:549558.
1990

Test for batchtobatch variation in stability analysis..
8:883890.
1989

Beyond sensitivity, specificity and statistical independence.
7:12891295.
1988

Commentary. Response to Dr Halperin on ‘models of the interaction of mortality and the evolution of risk factor distribution: A general stochastic process formulation’.
7:293295.
1988

Estimating hidden morbidity via its effect on mortality and disability..
7:325336.
1988

Models of the interaction of mortality and the evolution of risk factor distribution: a general stochastic process formulation..
7:239256.
1988

The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model..
4:3946.
1985

Tying clinical research to patient care by use of an observational database..
3:375387.
1984

Regression modelling strategies for improved prognostic prediction..
3:143152.
1984

Strategies for analysing ecological health data: models of the biological risk of individuals..
1:163181.
1982

Discussion: Frank W Rockhold and G Enas, data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations: George W Williams et al, monitoring of clinical trials and interim analyses from a drug sponsor's point of view
1993